Other Hungarian IBD Study Group members: Semmelweis University, 1st Department of Medicine, Budapest: Peter Fuszek, Henrik Csaba Horvath, Peter Vargha, Ferenc Szalay; Csolnoky F. County Hospital, 1st Department of Medicine, Veszprém: Zsuzsanna Erdelyi, Gabor Mester, Csaba Molnar, Tunde Pandur;; University of Szeged, 1st Department of Medicine, Szeged: Ferenc Nagy, Janos Lonovics; Department of Gastroenterology and Surgery, St Margit Hospital, Budapest: Demeter, Levente Balint, Pal Demeter, Ferenc Huoranszky, Istvan Dobo; Semmelweis University, 2nd Department of Medicine, Semmelweis University, Budapest: Laszlo Herszenyi, Annamaria Nemeth.
Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients
Version of Record online: 6 APR 2007
Copyright © 2007 Crohn's & Colitis Foundation of America, Inc.
Inflammatory Bowel Diseases
Volume 13, Issue 8, pages 984–992, August 2007
How to Cite
Papp, M., Altorjay, I., Norman, G. L., Shums, Z., Palatka, K., Vitalis, Z., Foldi, I., Lakos, G., Tumpek, J., Udvardy, M. L., Harsfalvi, J., Fischer, S., Lakatos, L., Kovacs, A., Bene, L., Molnar, T., Tulassay, Z., Miheller, P., Veres, G., Papp, J. and Lakatos, P. L. (2007), Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients. Inflamm Bowel Dis, 13: 984–992. doi: 10.1002/ibd.20146
- Issue online: 6 JUL 2007
- Version of Record online: 6 APR 2007
- Manuscript Accepted: 19 FEB 2007
- Manuscript Received: 16 JAN 2007
- atypical pANCA;
- disease phenotype;
Background: Antibodies directed against Saccharomyces cerevisiae (ASCA), perinuclear components of neutrophils (pANCA), and porin protein C of Escherichia coli (anti-OmpC) are reported to be associated with disease phenotype and may be of diagnostic importance in inflammatory bowel disease (IBD). Since limited data are available from Eastern Europe, we assessed the above antibodies in Hungarian IBD patients.
Methods: In all, 653 well-characterized, unrelated consecutive IBD patients (Crohn's disease [CD]: 558, m/f: 263/295, duration: 8.1 ± 10.7 years; ulcerative colitis [UC]: 95, m/f: 44/51, duration: 8.9 ± 9.8 years) and 100 healthy subjects were investigated. Sera were assayed for anti-Omp and ASCA by enzyme-linked immunosorbent assay (ELISA) and ANCA by indirect immunofluorescence assay (IIF). TLR4 and NOD2/CARD15 variants were tested by polymerase chain reaction/restriction fragment length polymorphism (PCR-RFLP). Detailed clinical phenotypes were determined by reviewing the medical charts.
Results: Anti-Omp, ASCA, and atypical pANCA antibodies were present in 31.2%, 59.3%, and 13.8% of CD, 24.2%, 13.7%, and 48.5% of UC patients, and in 20%, 16%, and 5.6% of controls, respectively. ASCA and anti-Omp positivity were associated with increased risk for CD (odds ratio [OR]ASCA = 7.65, 95% confidence interval [CI]: 4.37–13.4; OROmp = 1.81, 95% CI: 1.08–3.05). In a logistic regression analysis, anti-Omp and ASCA were independently associated with ileal and noninflammatory disease, but not with a risk for surgery or response to steroids or infliximab. A serology dosage effect was also observed. ASCA and anti-Omp antibodies were associated with NOD2/CARD15, in addition to a gene dosage effect. No associations were found in UC.
Conclusions: Serological markers were useful in the differentiation between CD and UC in an Eastern European IBD cohort. Reactivity to microbial components was associated with disease phenotype and NOD2/CARD15 genotype, further supporting the role of altered microbial sensing in the pathogenesis of CD.
(Inflamm Bowel Dis 2007)